200815-49-2 (酒石酸福莫特罗,Arformoterol tartrate)

酒石酸福莫特罗;N-[2-羟基-5-[(1R)-1-羟基-2-[(1R)-2-(4-甲氧基苯基)-1-甲基乙基]氨基]乙基]苯基]甲酰胺-L-(+)-酒石酸盐;N-(A,A-二甲基苯乙基)甲酰胺;WITEGABA032酒石酸福莫特罗标准品;阿福特罗;福莫特罗酒石酸盐 标准品;酒石酸阿福莫特罗;酒石酸阿福特罗;酒石酸福莫特罗标准品;

Arformoterol tartrate;(R,R)-Formoterol tartrate;N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1);(2R,3R)-2,3-dihydroxybutanedioic acid,N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);(R,R)-Arformoterol tartrate;Arformoterol tartrate (USAN);Brovana;Brovana (TN);Brovana Inhalation Solution;UNII-5P8VJ2I235;N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);Arformotero ltartrate;Formoterol r,r-form l-tartrate;DTXCID6096394;s5217;BA171831;Q27262686;(R,R)-Formoterol tartrate; N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1);AKOS005145740;ARFORMOTEROL TARTRATE [ORANGE BOOK];D02981;5P8VJ2I235;ARFORMOTEROL TARTRATE [VANDF];[(2R)-2-(3-formamido-4-hydroxyphenyl)-2-hydroxyethyl]-[(2R)-1-(4-methoxyphenyl)propan-2-yl]azanium;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate;N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide L-tartrate;200815-49-2;Arformoterol Tartrate Inhalation Solution;DTXSID80173903;Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);Arformoterol Tartrate [USAN];ARFORMOTEROL TARTRATE [WHO-DD];FORMOTEROL R,R-FORM L-TARTRATE [MI];FCSXYHUNDAXDRH-OKMNHOJOSA-N;Q-101035;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2R,3R)-2,3-dihydroxybutane dioate;BS-42158;ARFORMOTEROL TARTRATE (MART.);Arformoterol Tartrate Inhalation;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2R,3R)-2,3-dihydroxybutanedioate;ARFORMOTEROL TARTRATE [MART.];(2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;CCG-269651;(-)-N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide hydrogen (2R,3R)-2,3-dihydroxybutanedioate (salt);Arformoterol tartrate, >=98% (HPLC);

MFCD07785830

FCSXYHUNDAXDRH-OKMNHOJOSA-N

1S/C19H24N2O4.C4H6O6/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-1(3(7)8)2(6)4(9)10/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+;1-,2-/m11/s1

O[C@H](C1C=CC(=C(C=1)NC=O)O)CN[C@H](C)CC1C=CC(=CC=1)OC.O[C@@H](C(=O)O)[C@H](C(=O)O)O